trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'destiny,crc,02']
 t-dxd in her2+ #mcrc: destiny-crc02 phs-ii study #asco23 122 pts, &gt;80% ras wt, &gt;3/4 lines, 20% prior her2 5.4 &amp; 6.4 mg/kg t-dxd arms corr 37.8% vs 27.5%, mpfs 5.8 vs 5.5 mo mos 13.4 mo vs nr promising activity, independent of ras status 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology